

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2664080

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
GILEAD PALO ALTO, INC.		12/17/2013
RECEIVING PARTY DATA		
Name:	GILEAD SCIENCES, INC.	
Street Address:	333 LAKESIDE DRIVE	
City:	FOSTER CITY	
State/Country:	CALIFORNIA	
Postal Code:	94404	
PROPERTY NUMBERS Total: 37		
Property Type	Number	
Application Number:	13655252	
Application Number:	12052381	
Application Number:	13286069	
Application Number:	14014169	
Application Number:	60815755	
Application Number:	60606675	
Application Number:	60848294	
Application Number:	60889717	
Application Number:	60783575	
Application Number:	14046847	
Application Number:	60348222	
Application Number:	60691408	
Application Number:	60619439	
Application Number:	60841842	
Application Number:	13591008	

CH \$1480.00 13655252

Application Number:	61771702
Application Number:	13848614
Application Number:	13970372
Application Number:	12030389
Application Number:	12030587
Application Number:	14020736
Application Number:	13190300
Application Number:	60847865
Application Number:	60401408
Application Number:	11681378
Patent Number:	5840875
Patent Number:	5432058
Patent Number:	5521303
Patent Number:	6599283
Patent Number:	5679375
Patent Number:	5484777
Patent Number:	5792832
Patent Number:	6677343
Patent Number:	7449473
Patent Number:	5616570
Patent Number:	5063210
Patent Number:	5017565

CORRESPONDENCE DATA

Fax Number: (650)815-2601
Phone: (650) 815-2600
Email: rmena@sheppardmullin.com
Correspondence will be sent via US Mail when the email attempt is unsuccessful.
Correspondent Name: SHEPPARD MULLIN RICHTER & HAMPTON LLP
Address Line 1: 379 LYTTON AVENUE
Address Line 4: PALO ALTO, CALIFORNIA 94301-1479

ATTORNEY DOCKET NUMBER:	37JD-193768 GPA-GSI
NAME OF SUBMITTER:	LORNA L. TANNER
Signature:	/Lorna L. Tanner/
Date:	12/31/2013

source=Gilead PA to GSI 12-17-2013#page1.tif
source=Gilead PA to GSI 12-17-2013#page2.tif
source=Gilead PA to GSI 12-17-2013#page3.tif
source=Gilead PA to GSI 12-17-2013#page4.tif
source=Gilead PA to GSI 12-17-2013#page5.tif
source=Gilead PA to GSI 12-17-2013#page6.tif
source=Gilead PA to GSI 12-17-2013#page7.tif
source=Gilead PA to GSI 12-17-2013#page8.tif
source=Gilead PA to GSI 12-17-2013#page9.tif
source=Gilead PA to GSI 12-17-2013#page10.tif
source=Gilead PA to GSI 12-17-2013#page11.tif
source=Gilead PA to GSI 12-17-2013#page12.tif
source=Gilead PA to GSI 12-17-2013#page13.tif
source=Gilead PA to GSI 12-17-2013#page14.tif
source=Gilead PA to GSI 12-17-2013#page15.tif
source=Gilead PA to GSI 12-17-2013#page16.tif
source=Gilead PA to GSI 12-17-2013#page17.tif
source=Gilead PA to GSI 12-17-2013#page18.tif
source=Gilead PA to GSI 12-17-2013#page19.tif
source=Gilead PA to GSI 12-17-2013#page20.tif
source=Gilead PA to GSI 12-17-2013#page21.tif
source=Gilead PA to GSI 12-17-2013#page22.tif
source=Gilead PA to GSI 12-17-2013#page23.tif
source=Gilead PA to GSI 12-17-2013#page24.tif
source=Gilead PA to GSI 12-17-2013#page25.tif
source=Gilead PA to GSI 12-17-2013#page26.tif
source=Gilead PA to GSI 12-17-2013#page27.tif
source=Gilead PA to GSI 12-17-2013#page28.tif
source=Gilead PA to GSI 12-17-2013#page29.tif
source=Gilead PA to GSI 12-17-2013#page30.tif
source=Gilead PA to GSI 12-17-2013#page31.tif
source=Gilead PA to GSI 12-17-2013#page32.tif
source=Gilead PA to GSI 12-17-2013#page33.tif
source=Gilead PA to GSI 12-17-2013#page34.tif
source=Gilead PA to GSI 12-17-2013#page35.tif
source=Gilead PA to GSI 12-17-2013#page36.tif
source=Gilead PA to GSI 12-17-2013#page37.tif
source=Gilead PA to GSI 12-17-2013#page38.tif
source=Gilead PA to GSI 12-17-2013#page39.tif
source=Gilead PA to GSI 12-17-2013#page40.tif
source=Gilead PA to GSI 12-17-2013#page41.tif
source=Gilead PA to GSI 12-17-2013#page42.tif
source=Gilead PA to GSI 12-17-2013#page43.tif
source=Gilead PA to GSI 12-17-2013#page44.tif
source=Gilead PA to GSI 12-17-2013#page45.tif
source=Gilead PA to GSI 12-17-2013#page46.tif

ASSIGNMENT – WORLDWIDE

WHEREAS Gilead Palo Alto, Inc., of 333 Lakeside Drive, Foster City, California 94404, (hereinafter "Assignor") is the owner of the Patents or Patent Applications, both U.S. and all foreign countries, listed in Exhibit A, as well as the inventions set forth therein, by virtue of a merger of Apex Merger Sub, Inc. with and into CV Therapeutics, Inc., under the name Gilead Palo Alto, Inc.;

WHEREAS Gilead Sciences, Inc., of 333 Lakeside Drive, Foster City, California 94404, (hereinafter referred to singly and collectively as "Assignee") is desirous of acquiring the full right, title and interest in and to said inventions and in and to said Patents or Patent Applications for U.S. and all foreign countries and especially the countries listed in Exhibit A;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Assignor, Assignor has sold, assigned, transferred and set over, and by these presents hereby sells, assigns, transfers and sets over to Assignee the entire right, title and interest in and to said inventions for U.S. and all foreign countries, and in and to said Patents and Patent Applications listed in Exhibit A, including any and all priority applications, divisional, continuation, continuation-in-part, reissues or extensions thereof, to be held and enjoyed by Assignee for its own use as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment not been made; the Commissioner or Director of U.S. and each foreign Patent Office is hereby authorized to transfer Assignee's interest to said Patents or Patent Applications to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the Assignor, Assignor hereby undertakes to execute and deliver to Assignee upon request all lawful documents which may be requested by Assignee, and to furnish Assignee with all facts relating to said invention as may be requested.

Executed this 17th day of December, 2013.



Signature

Daniel W. Collins

Name

Associate General Counsel,
Intellectual Property

Title

for

GILEAD PALO ALTO, INC.

333 Lakeside Drive

Foster City, California 94404

(ASSIGNOR)

State of California

County of San Mateo)

On December 17, 2013 before me, Susan Ahearn, Notary Public
(date) (insert name and title of the officer)


personally appeared Daniel W. Collins
(name(s) of signer(s))

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.


I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Susan Ahearn (Seal)



Executed this 17 day of December, 2013.



Signature

Daniel W. Collins

Name

Associate General Counsel,
Intellectual Property

Title

for

GILEAD SCIENCES, INC.
333 Lakeside Drive
Foster City, California 94404
(ASSIGNEE)

State of California

County of San Mateo _____)

On December 17, 2013 before me, Susan Ahearn, Notary Public
(date) (insert name and title of the officer)

personally appeared Daniel W. Collins
(name(s) of signer(s))

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/~~she~~/they executed the same in his/~~her~~/their authorized capacity(ies), and that by his/~~her~~/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Susan Ahearn (Seal)




EXHIBIT A

Atty. Dkt. No.	Gilead Ref. No.	Appl. No.	Patent No.	Title	Country
161629-P	865.P	61/503980		FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS	United States of America
191514-P	02-0171-PRO	60/382781		METHOD FOR TREATING DIABETES	United States of America
191514-P2	02-0171-US-P2	60/459332		METHOD FOR TREATING DIABETES	United States of America
191514-US	02-0171-US	10/443,314		METHOD FOR TREATING DIABETES	United States of America
191514-US2	02-0171-US-CON	12/755,931	8,314,104	METHOD OF TREATING DIABETES	United States of America
191514-US3	02-0171-CON2	13/655,252		METHOD OF TREATING DIABETES	United States of America
191515-P	08-0263-US-PRO	61/094359		METHOD OF TREATING ATRIAL FIBRILLATION	United States of America
191515-P2	08-0263-US-P2	61/108776		METHOD OF TREATING ATRIAL FIBRILLATION	United States of America
191515-US	08-0263-US	12/553841		METHOD OF TREATING ATRIAL FIBRILLATION	United States of America
191525-P	00-0080-US	60/183560		USE OF PARTIAL FATTY ACID OXIDATION INHIBITORS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE WITH OR WITHOUT ANGINA	United States of America
191525-P2	00-0080-US-A	60/219908		USE OF PARTIAL FATTY ACID OXIDATION INHIBITORS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE WITH OR WITHOUT ANGINA	United States of America
191525-US	00-0080-US-B	09/784559	6528511	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	United States of America
191525-US2	00-0080-US-T	10/228573	6677342	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	United States of America
191526-P	02-0165-US-PRO	60/370150		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	United States of America
191526-P2	02-0165-P2	60/408292		METHOD OF TREATING ARRHYTHMIAS	United States of America

191526-P3	02-0165-P3	60/422589		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	United States of America
191526-US	02-0165-US	10/406894		METHOD OF TREATING ARRHYTHMIAS	United States of America
191526-US2	02-0165-US-CON	12/556417		METHOD OF TREATING ARRHYTHMIAS	United States of America
191532-P	03-0195-US-PRO	60/642168		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	United States of America
191532-US	03-0195-US	11/326965		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS	United States of America
191533-P	07-0245-US-PRO	60/896477		USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES	United States of America
191533-P2	07-0243-P4	60/947613		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
191533-US	07-0245-US	12/030659		USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES	United States of America
191533-US2	07-0245-US-CON	12/912527		USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES	United States of America
191534-US	02-0171-US-CIP	11/756,499		METHOD OF TREATING DIABETES	United States of America
191535-P2	07-0246-US-PRO	60/896478		USE OF RANOLAZINE FOR THE TREATMENT OF NON-CORONARY MICROVASCULAR DISEASES	United States of America
191535-US	07-0246-US	12/030699		USE OF RANOLAZINE FOR THE TREATMENT OF NON-CORONARY MICROVASCULAR DISEASES	United States of America
191536-P	07-0244-US-PRO	60/896466		USE OF RANOLAZINE FOR REDUCING BRAIN-TYPE NATRIURETIC PEPTIDE	United States of America
191536-P2	07-0244-US-P2	60/896845		USE OF RANOLAZINE FOR REDUCING BRAIN-TYPE NATRIURETIC PEPTIDE	United States of America
191536-P3	07-0244-US-P3	60/941210		USE OF RANOLAZINE FOR REDUCING BRAIN-TYPE NATRIURETIC PEPTIDE	United States of America
191536-US	07-0244-US	12/052381		USE OF RANOLAZINE FOR REDUCING BRAIN-TYPE NATRIURETIC PEPTIDE	United States of America

191536-US2	07-0244-US-R	12/054334		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	United States of America
191538-P	00-0078-US	60/184296		PARTIAL A2A ADENOSINE RECEPTOR (ADOR) AGONIST	United States of America
191538-P2	00-0078-US-A	60/219876		LOW AFFINITY A2A RECEPTOR AGONISTS	United States of America
191538-US	00-0078-US-B	09/792617		METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2A RECEPTOR	United States of America
191538-US2	00-0078-US-D	10/614702		METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2A RECEPTOR	United States of America
191538-US3	00-0078-US-D1	11/070768	7582617	MYOCARDIAL PERFUSION IMAGING METHOD	United States of America
191538-US4	00-0078-US-DCON	12/435176	8071566	METHODS OF CORONARY IMAGING, AS AMENDED	United States of America
191538-US5	00-0078-DCON2	13/286069		METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2A RECEPTOR	United States of America
191538-US6	00-0078-DCON3-TRK1	13/525223		METHODS OF MYOCARDIAL PERFUSION IMAGING	United States of America
191538-US7	00-0078-DCON4	14/014,169		METHODS OF MYOCARDIAL PERFUSION IMAGING	United States of America
191539-P	04-0869-US	60/620577		USE OF A2A ADENOSINE RECEPTOR AGONISTS	United States of America
191539-US	04-0869-US-A	11/253322	7655636	USE OF A2A ADENOSINE RECEPTOR AGONISTS	United States of America
191539-US2	04-0869-US-CON	12/637583	8106029	USE OF A2A ADENOSINE RECEPTOR AGONISTS	United States of America
191539-US3	04-0869-CON2-US	13/333789		USE OF A2A ADENOSINE RECEPTOR AGONISTS	United States of America
191540-P	06-0454-US	60/815755		USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA	United States of America
191540-US	06-0454-US-A	11/766964		USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA	United States of America

191559-P	03-0192-US-PRO	60/606675		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR	United States of America
191559-US	03-0192-US	11/216506		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR	United States of America
191560-US	01-0163-US-CIP4	12/013348		A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191563-P	06-0230-US-PRO	60/848294		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	United States of America
191563-P2	06-0230-US-P2	60/889717		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	United States of America
191563-US	06-0230-US	11/864437		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	United States of America
191564-US	01-0163-US-CIP2	10/719102	7125993	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191564-US2	01-0163-US-CP2D	11/508592	7521554	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191564-US3	01-0163-US-C2D2	12/361409		A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191565-P	05-0221-US-PRO	60/783575		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191565-US	05-0221-US	11/687236	7795268	METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191565-US2	05-0221-US-DIV	12/853510	8188099	METHOD OF DECREASING HEPATOTOXIC SIDE EFFECTS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191565-US3	05-0221-CON	13/407616		METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191565-US4	05-0221-CON	14/046847		METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191566-P	01-0163-US-PRO	60/348222		A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191566-US	01-0163-US	10/290921	6825349	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America

191566-US2	01-0163-US-DIV	10/947708	7105665	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191568-US	01-0163-US-CIP	10/431167	6977300	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191568-US2	01-0163-US-CON	11/189202	7317017	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191568-US3	01-0163-US-CON2	11/949229	7795269	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191568-US4	01-0163-US-DIV2	11/950740	7741331	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191568-US5	01-0163-US-CON3	12/776642		A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191568-US6	01-0163-CON4-US	13/016425		A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191568-US7	01-0163-CON5-US	13/169834	8324224	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191568-US8	01-0163-CON6-US	13/666826		A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191571-P	04-0209-US-PRO	60/691408		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191571-US	04-0209-US	11/453414	7625881	PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191571-US2	04-0209-USCON	12/618390		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191571-US3	04-0209-US-CON2	13/011446	8143249	PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191572-P	04-0207-US--PRO	60/619439		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191572-US	76729	11/251450		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
191572-US2	04-0207-US-CON	12/605783	8466129	METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America

191580-P	07-0237-US-PRO	60/878529		MYOCARDIAL PERFUSION IMAGING	United States of America
191580-US	07-0237-US	11/969047		MYOCARDIAL PERFUSION IMAGING	United States of America
191587-P	06-0222-US-PRO	60/841842		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	United States of America
191587-US	06-0222-US	11/848743		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	United States of America
191587-US2	06-0222-US-CIP	12/163099		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	United States of America
191627-US	99-0423-US	09/338185	6403567	N-PYRAZOLE A2A ADENOSINE RECEPTOR AGONISTS	United States of America
191628-P	05-0220-PRO	60/765114		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
191628-US	05-0220-CIP	11/750295	7671192	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
191628-US2	05-0220-CON	12/687077	7956179	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
191628-US3	05-0220-CON3	13/092812	8268988	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
191628-US4	05-0220-CIP-CON3	13/591008		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
191630-US	99-0424-US	09/338327	6214807	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
191630-US2	99-0424-US-E	09/812176	6855818	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
191630-US3	99-0424-US-T	10/018758	6770634	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
191630-US4	99-0424-US-T1	10/813535	7109180	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
191630-US5	99-0424-US-T2	11/522120	7553823	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America

191630-US6	99-0424-US-T2C2	12/491791		C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
191853-P	1012.P	61/771702		USE OF IKACH BLOCKERS FOR THE TREATMENT OF CARDIAC DISEASES	United States of America
192131-2	02-0478-US	60/399176		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	United States of America
192131-P	02-0479-US	60/399177		LOW DOSAGE MYOCARDIAL PERFUSION IMAGING AGENT	United States of America
192131-P3	02-0479-US-A	60/426902		LOW DOSAGE MYOCARDIAL PERFUSION IMAGING AGENT	United States of America
192131-P4	02-0479-US-B	60/459803		MYOCARDIAL PERFUSION IMAGING METHOD	United States of America
192131-US	02-0479-US-C	10/629368	7683037	MYOCARDIAL PERFUSION IMAGING METHOD	United States of America
192131-US2	02-0479-US-CON	12/695096	8183226	MYOCARDIAL PERFUSION IMAGING METHOD	United States of America
192132-US	02-0479-US-E	10/766403		MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS	United States of America
192132-US2	02-0479-US-CON2	12/749328	8133879	MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS	United States of America
192132-US3	02-0479-US-CON3	13/361775	8470801	MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS	United States of America
192132-US4	02-0479-US-CON4	13/848614		MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS	United States of America
192786-P2	05-0220-P2	60/801857		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
192786-US	05-0220-US	11/701699	7732595	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
192786-US2	05-0220-CON2	12/765623	8106183	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
192786-US3	05-0220-CON4	13/333872	8524883	MONOHYDRATE OF (1-{9-[(4S,2R,3R,5R)-3,4-DIHYDROXY-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6-AMINOPURIN-2-YL}PYRAZOL-4-YL)-N-METHYLCARBOXAMIDE	United States of America

192786-US4	05-0220-CON5	13/970,372		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
192807-P	07-0242-PRO	60/893121		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
192807-US	07-0238-US	12/030389		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
192807-US4	07-0238-US-1CIP	12/370442		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
192808-US	07-0238-US-2	12/030587		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
192809-US	07-0238-US-1	12/030468		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
192809-US2	07-0238-US-1CON	12/579956		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
192811-P	07-0243-P	60/894903		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
192811-P2	07-0243-P2	60/914645		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
192811-P3	07-0243-P3	60/941219		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
192812-US	99-0423-US-S	10/018446	6642210	N-Pyrazole A2A RECEPTOR AGONISTS	United States of America
192812-US2	99-0423-US-S1	10/652378	7183264	N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
192812-US3	99-0423-US-S2	11/252760	7144872	N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
192812-US4	99-0423-US-S3	11/588834	7655637	N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
192812-US5	99-0423-US-S4	12/637311		N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
192812-US6	99-0423-CON-S4	12/968110	8278435	N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America

192812-US7	99-0423-CON-S5	13/598451	8569260	N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
192812-US8	99-0423-CON-S6	14/020,736		N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
193175-US	01-0163-US-CIP3	10/942582	7304070	A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
193178-US	02-0165-US-CIP	11/932291		METHOD OF TREATING ARRHYTHMIAS	United States of America
193178-US2	02-0171-CIP2-US	13/190300		METHOD OF TREATING ARRHYTHMIAS	United States of America
193244-P	06-0231-PRO	60/847865		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	United States of America
INV-89573/US	02-0163-US-PRO	60/401408		A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
	95-0728-US	08/467007	5,840,875	KIDNEY NA/PO4 COTRANSPORTER ANTISENSE OLIGONUCLEOTIDE	United States of America
	92-0175-US	07/954864	5,432,058	METHOD FOR MEASURING HUMAN CHOLESTEROL ABSORPTION USING METABOLICALLY STABLE ISOTOPES	United States of America
	93-0473-US	08/322782	5,521,303	METHOD OF MANUFACTURING NON-ABSORBABLE SYNTHETIC SULFATED POLYSACCHARIDES	United States of America
	00-0001-US	09/848809	6,599,283	METHOD OF PREVENTING REPERFUSION INJURY	United States of America
	05-0221-US	11/687236	7,795,268	METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
	94-0631-US	08/481751	5,679,375	METHOD OF TREATING ULCERS WITH SULFATED POLYSACCHARIDES	United States of America
	03-0192-US	11/216506		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America

	00-0078- DCON3-TRK1	13/525223	8,536,150	METHODS OF MYOCARDIAL PERFUSION IMAGING	United States of America
	05-0220- CON4	13/333872	8,524,883	MONOHYDRATE OF (1-{9-[(4S,2R,3R,5R)-3,4- DIHYDROXY-5-(HYDROXYMETHYL)OXOLAN-2- YL]-6-AMINOPURIN-2-YL}PYRAZOL-4-YL)-N- METHYLCARBOXAMIDE	United States of America
	89-0200-US-P	08/167725	5,484,777	PANCREATIC CHOLESTEROL ESTERASE INHIBITOR	United States of America
	00-0080-US-B	09/784559	6,528,511	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	United States of America
	89-0852-US-J	08/461881	5,792,832	PEPTIDES FROM MAMMALIAN PANCREATIC CHOLESTEROL ESTERASE	United States of America
	05-0219-US	11/681378		SUBSTITUTED BICYCLIC AND TRICYCLIC THIENO [2,3-D]PYRMADINES AS A2A ADENOSINE RECEPTOR ANTAGONISTS	United States of America
	00-0132-US-A	09/791262	6,677,343	SUBSTITUTED PIPERAZINE COMPOUNDS	United States of America
	03-0191-US	10/973167	7,449,473	SUBSTITUTED PYRROLO[3,2-D]PYRIMIDIN-2,4- DIONES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	United States of America
	03-0195-US	11/326965		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS	United States of America
	04-0869-US-A	01/253322	7,655,636	USE OF A2A ADENOSINE RECEPTOR AGONISTS	United States of America
	89-0200-US-R	08/283723	5,616,570	USE OF NON-ABSORBABLE SYNTHETIC SULFATED POLYSACCHARIDES TO DECREASE CHOLESTEROL ABSORPTION	United States of America
	89-0200-US-B	07/429398	5,063,210	USE OF SULFATED POLYSACCHARIDES TO DECREASE CHOLESTEROL AND FATTY ACID ABSORPTION	United States of America
	89-0200-US	07/340868	5,017,565	USE OF SULFATED POLYSACCHARIDES TO INHIBIT PANCREATIC CHOLESTEROL ESTERASE	United States of America
	07-0249-US- CON	12/702,825		SUBSTITUTED HETEROCYCLIC COMPOUNDS	United States of America

Atty. Dkt. No.	Gilead Ref. No.	Appl. No.	Patent No.	Title	Country
191514-AU	02-0171-AU	2003248558	2003248558	METHOD OF TREATING DIABETES	Australia
191514-BR	02-0171-BR	PI0311161-0		METHOD OF TREATING DIABETES	Brazil
191514-CA	02-0171-CA	2486712	2486712	ADMINISTRATION OF A PARTIAL FATTY ACID INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES	Canada
191514-CN	02-0171-CN	03811323.6	ZL 03811323.6	USE OF RANOLAZINE IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES	China
191514-EP	02-0171-EP	03755446.6		ADMINISTRATION OF A PARTIAL FATTY ACID INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES	EPO
191514-EP2	02-0171-EPDIV	10011229.1		ADMINISTRATION OF A PARTIAL FATTY ACID INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES	EPO
191514-HK	02-0171-HK	05107050.7		ADMINISTRATION OF A PARTIAL FATTY ACID INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES	Hong Kong
191514-IL	02-0171-IL	165304	165304	USE OF COMPOUND OF FORMULA I FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION OF TREATING DIABETES	Israel
191514-IL3	99349	59821		METHOD OF TREATING DIABETES	New Zealand
191514-JP	02-0171-JP	2004-506805	4546824	ADMINISTRATION OF A PARTIAL FATTY ACID INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES	Japan
191514-KR	02-0171-KR	2004-7018803	1030943	ADMINISTRATION OF A PARTIAL FATTY ACID INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES	South Korea
191514-MX	02-0171-MX	PA/a/2004/011530	288904	ADMINISTRATION OF A PARTIAL FATTY ACID INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES	Mexico
191514-NO	02-0171-NO	2004-5554	330336	METHOD OF TREATING DIABETES	Norway
191514-NZ	02-0171-NZ	536678	536678	METHOD OF TREATING DIABETES	New Zealand
191514-RU	02-0171-RU	2004133670	2320343	METHOD OF TREATING DIABETES	Russian Federation
191514-SG	02-0171-SG	200406678-3	107988	ADMINISTRATION OF A PARTIAL FATTY ACID INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES	Singapore
191514-WO	02-0171-WO	PCT/US2003/016277		ADMINISTRATION OF A PARTIAL FATTY ACID INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES	PCT
191514-ZA	02-0171-ZA	2004/9331	2004/9331	METHOD OF TREATING DIABETES	South Africa

191515-CA	08-0263-CA	2735653		METHOD OF TREATING ATRIAL FIBRILLATION	Canada
191515-EP	08-0263-EP	09792242.1		METHOD OF TREATING ATRIAL FIBRILLATION	EPO
191515-HK	08-0263-HK	11113688.7		METHOD OF TREATING ATRIAL FIBRILLATION	Hong Kong
191515-JP	08-0263-JP	2011-526201		METHOD OF TREATING ATRIAL FIBRILLATION	Japan
191515-WO	08-0263-WO	PCT/US2009/055924		METHOD OF TREATING ATRIAL FIBRILLATION	PCT
191525-AR	00-0080-AR-D	P010100738		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Argentina
191525-AU	00-0080-AU-F	41505/01	778203	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Australia
191525-BR	00-0080-BR-J	PI0108452-6		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Brazil
191525-CA	00-0080-CA-G	2398691		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Canada
191525-CN	00-0080-CN-I	01805149.9	ZL1805149.9	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	China
191525-EP	00-0080-EP-K	01912758.8		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	EPO
191525-EP2	00-0080-EP-KDIV	08018568.9		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	EPO
191525-HK	00-0080-HK-U	03100016.7		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Hong Kong
191525-HK2	00-0080-HK-DIV	09108304.5		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Hong Kong
191525-IL	00-0080-IL-O	151014		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Israel
191525-JP	00-0080-JP-H	2001-559446		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Japan
191525-KR	00-0080-KR-L	2002-7010748		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	South Korea
191525-MX	00-0080-MX-M	PA/a/007639	264322	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Mexico
191525-NO	00-0080-NO-N	20023879		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Norway
191525-NZ	00-0080-NZ-P	520780	520780	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	New Zealand
191525-SG	00-0080-SG-Q	200204874-2	91054	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Singapore
191525-TR	00-0080-TR-R	2002/01998	200201998	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	Turkey

191525-TW	00-0080-TW-C	90103593	I235655	PARTIAL FATTY ACID OXIDATION INHIBITORS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE	Taiwan
191525-WO	00-0080-WO-E	PCT/US2001/004887		PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	PCT
191525-ZA	00-0080-ZA-S	2002/6451	2002/6451	PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE	South Africa
191526-AL1	02-0165-AL	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Albania
191526-AL2	02-0165-AL-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Albania
191526-AT1	02-0165-AT	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Austria
191526-AT2	02-0165-AT-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Austria
191526-AU	02-0165-AU	2003230810	2003230810	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Australia
191526-AU2	02-0165-AU-DIV2	2011202135		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Australia
191526-AU3	02-0165-AU-DIV	2009201065	2009201065	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Australia
191526-BE1	02-0165-BE	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Belgium
191526-BE2	02-0165-BE-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Belgium
191526-BG1	02-0165-BG	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Bulgaria
191526-BG2	02-0165-BG-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Bulgaria
191526-CA	02-0165-CA	2481192	2481192	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Canada

191526-CH1	02-0165-CH	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Switzerland
191526-CH2	02-0165-CH-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Switzerland
191526-CN	02-0165-CN	03807871.6	ZL03807871.6	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	China
191526-CN2	02-0165-CN-DIV	200910171650.1		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	China
191526-CY1	02-0165-CY	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Cyprus
191526-CY2	02-0165-CY-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Cyprus
191526-CZ1	02-0165-CZ	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Czech Republic
191526-CZ2	02-0165-CZ-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Czech Republic
191526-DE1	02-0165-DE	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Germany
191526-DE2	02-0165-DE-DIV	08004276.5	60332975.6-08	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Germany
191526-DK1	02-0165-DK	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Denmark
191526-DK2	02-0165-DK-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Denmark
191526-EE1	02-0165-EE	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Estonia
191526-EE2	02-0165-EE-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Estonia

191526-EP1	02-0165-EP	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	EPO
191526-EP2	02-0165-EP-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	EPO
191526-EP3	02-0165-EP-DIV2	10002699.6		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	EPO
191526-ES1	02-0165-ES	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Spain
191526-ES2	02-0165-ES-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Spain
191526-FI1	02-0165-FI	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Finland
191526-FI2	02-0165-FI-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Finland
191526-FR1	02-0165-FR	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	France
191526-FR2	02-0165-FR-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	France
191526-GB	02-0165-GB	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	United Kingdom
191526-GB2	02-0165-GB-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	United Kingdom
191526-GR1	02-0165-GR	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Greece
191526-GR2	02-0165-GR-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Greece
191526-HK	02-0165-HK-DIV	08113291.1	HK1120390	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Hong Kong

191526-HK2	02-0165-DIV2-HK	10111847.0		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Hong Kong
191526-HU1	02-0165-HU	03723907.6	E003955	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Hungary
191526-HU2	02-0165-HU-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Hungary
191526-IE1	02-0165-IE	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Ireland
191526-IE2	02-0165-IE-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Ireland
191526-IL	02-0165-IL	164388	164388	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Israel
191526-IL2	02-0165-IL-DIV	197406		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Israel
191526-IT1	02-0165-IT	03723907.6	7208/BE/2008	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Italy
191526-IT2	02-0165-IT-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Italy
191526-JP	02-0165-JP	2003-583420	4608217	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Japan
191526-KR	02-0165-KR	2004-7015749		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	South Korea
191526-KR2	02-0165-KRD	2010-7021063		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	South Korea
191526-LT1	02-0165-LT	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Lithuania
191526-LT2	02-0165-LT-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Lithuania
191526-LU1	02-0165-LU	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Luxembourg

191526-LU2	02-0165-LU-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Luxembourg
191526-LV1	02-0165-LV	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Latvia
191526-LV2	02-0165-LV-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Latvia
191526-MC1	02-0165-MC	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Monaco
191526-MC2	02-0165-MC-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Monaco
191526-MK1	02-0165-MK	03723907.6	903026	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Macedonia
191526-MK2	02-0165-MK-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Macedonia
191526-MX	02-0165-MX	PA/a/2004/009637	261650	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Mexico
191526-MX2	02-0165-MX-DIV	MX/a/2008/011192	302534	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Mexico
191526-NL1	02-0165-NL	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Netherlands
191526-NL2	02-0165-NL-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Netherlands
191526-NO	02-0165-NO	20044783	330953	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Norway
191526-NZ	02-0165-NZ	535610	535610	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	New Zealand
191526-PT1	02-0165-PT	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Portugal

191526-PT2	02-0165-PT-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Portugal
191526-RO1	02-0165-RO	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Romania
191526-RO2	02-0165-RO-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Romania
191526-RU	02-0165-RU	2004129589	2325161	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Russian Federation
191526-SE1	02-0165-SE	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Swededn
191526-SE2	02-0165-SE-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Swededn
191526-SI1	02-0165-SI	P200331293	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Slovenia
191526-SI2	02-0165-SI-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Slovenia
191526-SK1	02-0165-SK	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Slovakia
191526-SK2	02-0165-SK-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Slovakia
191526-TR1	02-0165-TR	03723907.6	1490066	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	Turkey
191526-TR2	02-0165-TR-DIV	08004276.5	1930007	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF EARLY AFTERDEPOLARISATIONS (EADs)	Turkey
191526-WO	02-0165-WO	PCT/US2003/010434		USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	PCT
191526-ZA	02-0165-ZA	2004/7972	2004/7972	USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ARRHYTHMIAS	South Africa

191532-AU	03-0195-AU	2006203890		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Australia
191532-BR	03-0195-BR	PI0606403-5		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Brazil
191532-CA	03-0195-CA	2593593		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Canada
191532-CN	03-0195-CN	200680001833.3		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	China
191532-EP	03-0195-EP	06717674.6		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	EPO
191532-GE	03-0195-GE	AP2006010166	4784	SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Georgia
191532-HK	02-0165-HK-DIV	08103463.4		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Hong Kong
191532-IL	03-0195-IL	184460		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Israel
191532-IN	03-0195-IN	2963/KOLNP/2007		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	India
191532-JP	03-0195-JP	2007-550511		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Japan
191532-KR	03-0195-KR	2007-7015511		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	South Korea
191532-MX	03-0195-MX	MX/a/2007/008162		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Mexico
191532-NO	03-0195-NO	20074037		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Norway
191532-NZ	03-0195-NZ	556366		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	New Zealand
191532-RU	03-0195-RU	2007125656	2384332	SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Russian Federation
191532-SG	03-0195-SG	200705077-6		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Singapore

191532-UA	03-0195-UA	a200707605	90875	SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	Ukraine
191532-WO	03-0195-WO	PCT/US2006/000503		SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	PCT
191532-ZA	03-0195-ZA	2007/05530	2007/05530	SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING RANOLAZINE	South Africa
191533-CA	07-0245-CA	2678319		USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES	Canada
191533-EP	07-0245-EP	08729763.6		USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES	EPO
191533-HK	07-0245-HK	10104570.8		USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES	Hong Kong
191533-JP	07-0245-JP	2009-549700		USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES	Japan
191533-WO	07-0245-WO	PCT/US2008/053845		USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES	PCT
191534-AU	02-0171-AU-CIP	2007354300		METHOD OF TREATING DIABETES	Australia
191534-BR	02-0171-BR-CIP	PI0721741-2		METHOD OF TREATING DIABETES	Brazil
191534-CA	02-0171-CA-CIP	2687381		METHOD OF TREATING DIABETES	Canada
191534-CN	02-0171-CN-CIP	200780053142.2		METHOD OF TREATING DIABETES	China
191534-CN2	02-0171-CN-DIV	200910171670.9		USE OF RANOLAZINE IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES	China
191534-EP	02-0171-EP-CIP	07797962.3		METHOD OF TREATING DIABETES	EPO
191534-HK	02-0171-HK-CIP	10107471.1		METHOD OF TREATING DIABETES	Hong Kong
191534-IL	02-0171-ILCIP	202002		METHOD OF TREATING DIABETES	Israel
191534-IL2	02-0171-IL-DIV2	213806		USE OF COMPOUND OF FORMULA I FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION OF TREATING DIABETES	Israel
191534-IL3	02-0171-IL-DIV	213809		USE OF COMPOUND OF FORMULA I FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION OF TREATING DIABETES	Israel
191534-JP	02-0171-JP-CIP	2010-510275		METHOD OF TREATING DIABETES	Japan
191534-KR	02-0171-KR-CIP	2009-7027359		METHOD OF TREATING DIABETES	South Korea

191534-MX	02-0171-MX-CIP	MX/a/2009/012957		METHOD OF TREATING DIABETES	Mexico
191534-NO	02-0171-NO-CIP	20093592		METHOD OF TREATING DIABETES	Norway
191534-NZ	02-0171-NZ-CIP	581034		METHOD OF TREATING DIABETES	New Zealand
191534-RU	02-0171-RU-CIP	2009149347	2442585	METHOD OF TREATING DIABETES	Russian Federation
191534-SG	02-0171-SG-CIP	200907411-3		METHOD OF TREATING DIABETES	Singapore
191534-WO	02-0171-WO-CIP	PCT/US2007/070140		METHOD OF TREATING DIABETES	PCT
191534-ZA	02-0171-ZA-CIP	2009/07778	2009/07778	METHOD OF TREATING DIABETES	South Africa
191535-CA	07-0246-CA	2678325		USE OF RANOLAZINE FOR THE TREATMENT OF NON-CORONARY MICROVASCULAR DISEASES	Canada
191535-EP	07-0246-EP	08743468.4		USE OF RANOLAZINE FOR THE TREATMENT OF NON-CORONARY MICROVASCULAR DISEASES	EPO
191535-HK	07-0246-HK	10104802.8		USE OF RANOLAZINE FOR THE TREATMENT OF NON-CORONARY MICROVASCULAR DISEASES	Hong Kong
191535-JP	07-0246-JP	2009-549702		USE OF RANOLAZINE FOR THE TREATMENT OF NON-CORONARY MICROVASCULAR DISEASES	Japan
191535-WO	07-0246-WO	PCT/US2008/053852		USE OF RANOLAZINE FOR THE TREATMENT OF NON-CORONARY MICROVASCULAR DISEASES	PCT
191536-AT	07-0244-AT-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Austria
191536-AU	07-0244-AU-R	2008260480		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Australia
191536-BE	07-0244-BE-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Belgium
191536-BG	07-0244-BG-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Bulgaria
191536-BR	07-0244-BR-R	Base PCT/US2008/0580		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Brazil
191536-CA	07-0244-CA-R	2689633		USE OF RANOLAZINE FOR REDUCING BRAIN-TYPE NATRIURETIC PEPTIDE	Canada
191536-CH	07-0244-CH-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Switzerland
191536-CN	07-0244-CN-R	200880100958		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	China
191536-CO	07-0244-CO-R	09-144.793		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Colombia

191536-CY	07-0244-CY-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Cypruss
191536-CZ	07-0244-CZ-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Czech Republic
191536-DE	07-0244-DE-R	08732776.3	6.02008E+11	RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Germany
191536-DN	07-0244-DK-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Denmark
191536-EA	07-0244-EA-R	200971073		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	EAPO
191536-EC	07-0244-EC-R	SP-09-9828		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Ecuador
191536-EE	07-0244-EE-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Estonia
191536-EP	07-0244-EP-R	08732776.3	2170333	RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	EPO
191536-ES	07-0244-ES-R	08732776.3	2170333	RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Spain
191536-FI	07-0244-FI-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Finland
191536-FR	07-0244-FR-R	08732776.3	2170333	RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	France
191536-GB	07-0244-R-GB	08732776.3	2170333	RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	United Kingdom
191536-GR	07-0244-R-GR	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Greece
191536-HK	07-0244-HK-R	10109528.0		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Hong Kong
191536-HR	07-0244-HR-R	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Croatia
191536-HU	07-0244-R-HU	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Hungary
191536-ID	07-0244-ID-R	W00200903667		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Indonesia
191536-IE	07-0244-R-IE	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Ireland
191536-IS	07-0244-R-IS	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Iceland
191536-IT	07-0244-IL-R	202493		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Israel
191536-IT2	07-0244-R-IT	08732776.3	2170333	RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Italy

191536-KR	07-0244-KR-R	10-2009-7027109		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	South Korea
191536-LT	07-0244-R-LT	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Lithuania
191536-LU	07-0244-R-LU	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Luxembourg
191536-LV	07-0244-R-LV	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Latvia
191536-MC	07-0244-R-MC	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Monaco
191536-MT	07-0244-R-MT	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Malta
191536-MX	07-0244-MX-R	MX/a/2009/013961		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Mexico
191536-NL	07-0244-R-NL	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Netherlands
191536-NO2	07-0244-R-NO	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Norway
191536-NZ	07-0244-NZ-R	581744		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	New Zealand
191536-PH	07-0244-PH-R	1-2009-502413		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Philippines
191536-PL	07-244-R-PL	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Poland
191536-PT	07-244-R-PT	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Portugal
191536-RO	07-244-R-RO	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Romania
191536-SE	07-244-R-SE	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Swededn
191536-SG	07-0244-SG-R	200908639-8		USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Singapore
191536-SI	07-244-R-SI	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Slovenia
191536-SK	07-244-R-SK	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Slovakia
191536-TR	07-244-R-TR	08732776.3		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Turkey
191536-UA	07-0244-UA-R	a 2009 13934		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	Ukraine
191536-WO	07-0244-WO-R	PCT/US2008/058063		RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	PCT

191536-WO2	07-0244-WO	PCT/US2008/057686		USE OF RANOLAZINE FOR REDUCING BRAIN-TYPE NATRIURETIC PEPTIDE	PCT
191536-ZA	07-0244-ZA-R	2009/08657	2009/08657	USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE	South Africa
191538-CA	00-0078-CA-E	2439222	2439222	IDENTIFICATION OF PARTIAL AGONISTS OF THE A2A ADENOSINE RECEPTOR	Canada
191538-CA2	00-0078-CA-DIV	2671940		IDENTIFICATION OF PARTIAL AGONISTS OF THE A2A ADENOSINE RECEPTOR	Canada
191538-WO	00-0078-WO-C	PCT/US2001/005831		IDENTIFICATION OF PARTIAL AGONISTS OF THE A2A ADENOSINE RECEPTOR	PCT
191539-AU	04-0869-AU	2005295437	2005295437	USE OF A2A ADENOSINE RECEPTOR AGONISTS	Australia
191539-CA	04-0869-CA-C	2583185		USE OF A2A ADENOSINE RECEPTOR AGONISTS	Canada
191539-CN	04-0869-CN	200580035640.5		USE OF A2A ADENOSINE RECEPTOR AGONISTS	China
191539-EP	04-0826-EP	05815368.5		USE OF A2A ADENOSINE RECEPTOR AGONISTS	EPO
191539-IL	04-0869-IL	182645		USE OF A2A ADENOSINE RECEPTOR AGONISTS	Israel
191539-JP	04-0869-JP	2007-537961		USE OF A2A ADENOSINE RECEPTOR AGONISTS	Japan
191539-KR	04-0869-KR	10-2007-7008782		USE OF A2A ADENOSINE RECEPTOR AGONISTS	South Korea
191539-MX	04-0869-MXD	MX/a/2007/004749		USE OF A2A ADENOSINE RECEPTOR AGONISTS	Mexico
191539-NO	04-0869-NO	20072540		USE OF A2A ADENOSINE RECEPTOR AGONISTS	Norway
191539-NZ	04-0869-NZ	554611		USE OF A2A ADENOSINE RECEPTOR AGONISTS	New Zealand
191539-RU	04-0869-RU	2007114908		USE OF A2A ADENOSINE RECEPTOR AGONISTS	Russian Federation
191539-SG	04-0869-SG	200702906-9		USE OF A2A ADENOSINE RECEPTOR AGONISTS	Singapore
191539-WO	04-0869-WO-B	PCT/US2005/037368		USE OF A2A ADENOSINE RECEPTOR AGONISTS	PCT
191539-ZA	04-0869-ZA	2007/03229	2007/03229	USE OF A2A ADENOSINE RECEPTOR AGONISTS	South Africa
191540-CA	06-0454-CA-B	2655310		USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA	Canada
191540-EP	06-0454-EP-B	07870996.1		USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA	EPO
191540-HK	06-0454-HK	09111398.6		USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA	Hong Kong
191540-JP	06-0454-JP-B	2009-516747		USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF ISCHEMIA	Japan
191540-JP2	06-0454-JPD	2012-228109		USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF ISCHEMIA	Japan
191540-MX	06-0454-MX-B	MX/a/2008/016254		USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA	Mexico

191540-WO	06-0454-WO-B	PCT/US2007/071882		USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA	PCT
191559-AL	03-0192-AL	05811901.7	4126	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Albania
191559-AT	03-0192-AT	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Austria
191559-AU	03-0192-AU	2005282860	2005282860	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191559-BA	03-0192-BA	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Bosnia and Herzegovina
191559-BE	03-0192-BE	05811901.7	789053	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Belgium
191559-BG	03-0192-BG	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Bulgaria
191559-CA	03-0192-CA	2578702		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Canada
191559-CH	03-0192-CH	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Switzerland
191559-CN	03-0192-CN	200580035564.8	2.0058E+11	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	China
191559-CY	03-0192-CY	05811901.7	1113388	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Cyprus
191559-CZ	03-0192-CZ	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Czech Republic
191559-DE	03-0192-DE	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Germany
191559-DK	03-0192-DK	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Denmark
191559-EE	03-0192-EE	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Estonia
191559-EP	03-0192-EP	05811901.7	1789053	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	EPO
191559-ES	03-0192-ES	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Spain
191559-FI	03-0192-FI	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Finland
191559-FR	03-0192-FR	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	France
191559-GB	03-0192-GB	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	United Kingdom
191559-GR	03-0192-GR	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Greece

191559-HK	03-0192-HK	07112965.9	1107261	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Hong Kong
191559-HR	03-0192-HR	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Croatia
191559-HU	03-0192-HU	05811901.7	15298	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Hungary
191559-IE	03-0192-IE	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Ireland
191559-IL	03-0192-IL	181634		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Israel
191559-IS	03-0192-IS	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Iceland
191559-IT	03-0192-IT	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Italy
191559-JP	03-0192-JP	2007-530269	4929173	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Japan
191559-JP2	03-0192-JPD	2011-195497		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Japan
191559-KR	03-0192-KR	2007-7004993	1247528	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	South Korea
191559-LT	03-0192-LT	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Lithuania
191559-LU	03-0192-LU	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Luxembourg
191559-LV	03-0192-LV	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Latvia
191559-MC	03-0192-MC	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Monaco
191559-MK	03-0192-MK	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Macedonia
191559-MX	03-0192-MX	MX/a/2007/002437	301304	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Mexico
191559-NL	03-0192-NL	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Netherlands
191559-NO	03-0192-NO	20071718		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Norway
191559-NZ	03-0192-NZ	553487		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand
191559-PL	03-0192-PL	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Poland
191559-PT	03-0192-PT	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Portugal

191559-RO	03-0192-RO	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Romania
191559-RS	03-0192-RS	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Serbia
191559-RU	03-0192-RU	2007107605	2385322	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Russian Federation
191559-SE	03-0192-SE	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Swededn
191559-SI	03-0192-SI	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Slovenia
191559-SK	03-0192-SK	05811901.7		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Slovakia
191559-TR	03-0192-TR	05811901.7	TR201209210T4	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Turkey
191559-WO	03-0192-WO	PCT/US2005/030838		METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	PCT
191559-ZA	03-0192-ZA	2007/01777	2007/01777	METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS	South Africa
191560-WO	01-0163-WO-CIP4	PCT/US2008/050930		A2B ADENOSINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER	PCT
191561-AL	01-0163-AL	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Albania
191561-AT	01-0163-AT-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Austria
191561-AU	01-0163-AU-WO02	2003249604	2003249604	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191561-AU2	01-0163-AUD-WO02	2011224104	2011224104	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191561-BE	01-0163-BE-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Belgium
191561-BG	01-0163-BG-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Bulgaria
191561-CA	01-0163-CA-WO2	2524778	2524778	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Canada
191561-CH	01-0163-CH-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Switzerland
191561-CN	01-0163-CN-WO2	03826411.0	ZL03826411.0	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	China
191561-CY	01-0163-CY-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Cypress
191561-CZ	01-0163-CZ-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Czech Republic

191561-DE	01-0163-DE-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Germany
191561-DK	01-0163-DK-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Denmark
191561-EE	01-0163-EE-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Estonia
191561-EP	01-0163-EP-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	EPO
191561-ES	01-0163-ES-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Spain
191561-FI	01-0163-FI-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Finland
191561-FR	01-0163-FR-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	France
191561-GB	01-0163-GB-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	United Kingdom
191561-GR	01-0163-GR-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Greece
191561-HK	76474	06108745.2	1092137	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Hong Kong
191561-HU	75878	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Hungary
191561-IE	01-0163-IE-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Ireland
191561-IL	01-0163-IL-WO02	171751		XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Israel
191561-IT	01-0163-IT-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Italy
191561-JP	01-0163-JP-WO02	2005-500296		XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Japan
191561-KR	01-0163-KR-WO2	2005-7020956		XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	South Korea
191561-LI	01-0163-LI-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Liechtenstein
191561-LT	01-0163-LT-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Lithuania
191561-LU	01-0163-LU-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Luxembourg
191561-LV	01-0163-LV-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Latvia
191561-MC	01-0163-MC-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Monaco

191561-MK	01-0163-WO02-MK	03817096.5	902959	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Macedonia
191561-MX	01-0163-MX-WO02	PA/a/2005/011860	261405	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Mexico
191561-NL	01-0163-NL-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Netherlands
191561-NZ	01-0163-WO2-NZ	PCT/US2003/014085	543416	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand
191561-NZ2	01-0163-NZ-WO2D	573577	573577	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand
191561-PL	01-0163-PL-WO02	P378983		XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Poland
191561-PT	01-0163-PT-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Portugal
191561-RO	01-0163-RO-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Romania
191561-RU	01-0163-RU-WO02	2005134232	2374247	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Russian Federation
191561-SE	01-0163-SE-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Swededn
191561-SI	01-0163-SI-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Slovenia
191561-SK	01-0163-SK-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Slovakia
191561-TR	01-0163-TR-WO02	03817096.5	1622908	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Turkey
191561-WO	01-0163-WO02	PCT/US2003/014085		XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	PCT
191561-ZA	01-0163-ZA-WO02	2005/08262	2005/08262	XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	South Africa
191563-CA	06-0230-CA	2663361		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	Canada
191563-EP	06-0230-EP	07843523.7		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	EPO
191563-HK	06-0230-HK	09111329.0		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	Hong Kong
191563-JP	06-0230-JP	2009-530646		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	Japan
191563-MX	06-0230-MX	MX/a/2009/003348		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	Mexico

191563-WO	06-0230-WO	PCT/US2007/079955		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	PCT
191564-AU	01-0163-CIP2-AU	2204292529	2004292529	A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191564-AU2	01-0163-CIP2-AUD	2011202523	2011202523	A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191564-BE	1-0163-BE-CIP2	04811022.5		A2B ADENOSINE RECEPTOR ANTAGONISTS	Belgium
191564-CA	01-0163-CA-CIP2	2546733		A2B ADENOSINE RECEPTOR ANTAGONISTS	Canada
191564-CH	1-0163-CH-CIP2	04811022.5		A2B ADENOSINE RECEPTOR ANTAGONISTS	Switzerland
191564-CN	01-0163-CN-CIP2	200480034277	100415748C	A2B ADENOSINE RECEPTOR ANTAGONISTS	China
191564-DE	1-0163-DE-CIP2	04811022.5	602004039168.9	A2B ADENOSINE RECEPTOR ANTAGONISTS	Germany
191564-EP	1-0163-EP-CIP2	04811022.5	1685132	PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PURINE DERIVATIVES USEFUL IN THE TREATMENT OF (INTER ALIA) CANCER, ASTHMA AND DIARRHEA	EPO
191564-ES	1-0163-ES-CIP2	04811022.5		A2B ADENOSINE RECEPTOR ANTAGONISTS	Spain
191564-FR	1-0163-FR-CIP2	04811022.5		A2B ADENOSINE RECEPTOR ANTAGONISTS	France
191564-GB	1-0163-GB-CIP2	04811022.5		A2B ADENOSINE RECEPTOR ANTAGONISTS	United Kingdom
191564-HK	01-0163-HK-CIP2	07100507.9	HK1093736	A2B ADENOSINE RECEPTOR ANTAGONISTS	Hong Kong
191564-IE	1-0163-IE-CIP2	04811022.5		A2B ADENOSINE RECEPTOR ANTAGONISTS	Ireland
191564-IL	01-0163-IL-CP2D	201210		A2B ADENOSINE RECEPTOR ANTAGONISTS	Israel
191564-IL2	01-0163-CIP2-IL	175759		A2B ADENOSINE RECEPTOR ANTAGONISTS	Israel
191564-IT	1-0163-IT-CIP2	04811022.5		A2B ADENOSINE RECEPTOR ANTAGONISTS	Italy
191564-JP	01-0163-JP-CIP2	2006-541295	4769728	A2B ADENOSINE RECEPTOR ANTAGONISTS	Japan
191564-KR	01-0163-KR-CIP2	2006-7009840	1140186	A2B ADENOSINE RECEPTOR ANTAGONISTS	South Korea
191564-MX	01-0163-CIP2-MX	PA/a/2006/005637	264837	A2B ADENOSINE RECEPTOR ANTAGONISTS	Mexico
191564-NZ	01-0163-NZ-CIP2	547357	547357	A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand
191564-RU	01-0163-RU-CIP2	2006117349		A2B ADENOSINE RECEPTOR ANTAGONISTS	Russian Federation
191564-TW	01-0163-TW-CIP2	93135764	93135764	A2B ADENOSINE RECEPTOR ANTAGONISTS	Taiwan
191564-WO	01-0163-WO-CIP2	PCT/US2004/038136		A2B ADENOSINE RECEPTOR ANTAGONISTS	PCT

191564-ZA	01-0163-ZA-CIP2	2006/04046	2006/04046	A2B ADENOSINE RECEPTOR ANTAGONISTS	South Africa
191565-AU	05-0221-AU	2007227021	2007227021	METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191565-AU2	05-0221-AUD	2012261721		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191565-CA	05-0221-CA	2646333		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Canada
191565-CN	05-0221--CN	20078000095	ZI 200780009507.1	METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	China
191565-EP	05-0221-EP	07758704.6		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	EPO
191565-EP2	05-0221-EP-DIV	11003658.9		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	EPO
191565-HK	05-0221-HK	09104848.7		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Hong Kong
191565-IL	05-0221-IL	194158		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Israel
191565-JP	05-0221-JP	2009-501667	5250848	METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Japan
191565-JP2	05-0221-JPD	2012-268193		METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Japan
191565-KR	05-0221-KR	2008-7022707		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	South Korea
191565-MX	05-0221-MX	MX/a/2008/011828	305999	METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Mexico
191565-MX2	05-0221-MXD	MX/a/2012/014305		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Mexico
191565-NO	05-0221-NO	20083968		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Norway
191565-NZ	05-0221-NZ	571324	571324	METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand

191565-RU	05-0221-RU	2008137279	2457842	METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Russian Federation
191565-WO	05-0221-WO	PCT/US2007/064182		METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	PCT
191565-ZA	05-0221-ZA	2008/07894	2008/07894	METHOD OF PREVENTING AND TREATING HEPATIC FIBROSIS USING A2B ADENOSINE RECEPTOR ANTAGONISTS	South Africa
191566-AL	01-0163-AL	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Albania
191566-AT	01-0163-AT	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Austria
191566-AU	01-0163-AU	2002/359365	2002/359365	A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191566-BE	01-0163-BE	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Belgium
191566-BG	01-0163-BG	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Bulgaria
191566-CA	01-0163-CA	2466477	2466477	A2B ADENOSINE RECEPTOR ANTAGONISTS	Canada
191566-CH	01-0163-CH	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Switzerland
191566-CN	01-0163-CN	02822258.X	ZL02822258.X	A2B ADENOSINE RECEPTOR ANTAGONISTS	China
191566-CY	01-0163-CY	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Cyprus
191566-CZ	01-0163-CZ	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Czech Republic
191566-DE	01-0163-DE	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Germany
191566-DK	01-0163-DK	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Denmark
191566-EE	01-0163-EE	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Estonia
191566-EP	01-0163-EP	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	EPO
191566-ES	01-0163-ES	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Spain
191566-FI	01-0163-FI	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Finland
191566-FR	01-0163-FR	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	France
191566-GB	01-0163-GB	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	United Kingdom
191566-GR	01-0163-GR	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Greece
191566-HK	01-0163-HK	05101136.8	1071127	A2B ADENOSINE RECEPTOR ANTAGONISTS	Hong Kong
191566-HU	01-0163-HU	P0401925		A2B ADENOSINE RECEPTOR ANTAGONISTS	Hungary
191566-IE	01-0163-IE	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Ireland
191566-IL	01-0163-IL	161867		A2B ADENOSINE RECEPTOR ANTAGONISTS	Israel
191566-IT	01-0163-IT	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Italy
191566-JP	01-0163-JP	2003-544050	4350517	A2B ADENOSINE RECEPTOR ANTAGONISTS	Japan

191566-KR	01-0163-KR	2004-7006955	937620	A2B ADENOSINE RECEPTOR ANTAGONISTS	South Korea
191566-LT	01-0163-LT	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Lithuania
191566-LU	01-0163-LU	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Luxembourg
191566-LV	01-0163-LV	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Latvia
191566-MC	01-0163-MC	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Monaco
191566-MK	01-0163-MK	02793897.6	904055	A2B ADENOSINE RECEPTOR ANTAGONISTS	Macedonia
191566-MX	01-0163-MX	PA/a/2004-004388	250505	A2B ADENOSINE RECEPTOR ANTAGONISTS	Mexico
191566-NL	01-0163-NL	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Netherlands
191566-NO	01-0163-NO	20042378	329692	A2B ADENOSINE RECEPTOR ANTAGONISTS	Norway
191566-NZ	01-0163-NZ	532816	532816	A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand
191566-PL	01-0163-PL	P370207		XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS	Poland
191566-PT	01-0163-PT	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Portugal
191566-RO	01-0163-RO	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Romania
191566-RU	01-0163-RU	2004114210	2318824	A2B ADENOSINE RECEPTOR ANTAGONISTS	Russian Federation
191566-SE	01-0163-SE	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Sweden
191566-SI	01-0163-SI	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Slovenia
191566-SK	01-0163-SK	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Slovakia
191566-TR	01-0163-TR	02793897.6	1444233	A2B ADENOSINE RECEPTOR ANTAGONISTS	Turkey
191566-WO	01-0163-WO	PCT/US2002/035880		A2B ADENOSINE RECEPTOR ANTAGONISTS	PCT
191566-ZA	01-0163-ZA	2004/3485	2004/3485	A2B ADENOSINE RECEPTOR ANTAGONISTS	South Africa
191571-AU	04-0209-AU	2006259411	2006259411	PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191571-CA	04-0209-CA	2612344		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	Canada
191571-CN	04-0209-CN	200680021338.9	20068002133	PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	China
191571-EP	04-0209-EP	06773161.2		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	EPO
191571-EP2	04-0209-EP-DIV	10011665.6		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	EPO
191571-HK	04-0209-HK	08109184.9		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	Hong Kong
191571-IL	04-0209-IL	188103		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	Israel
191571-IN	04-0209-IN	4878/KOLNP/2007		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	India

191571-JP	04-0209-JP	2008-517067	5044823	PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	Japan
191571-KR	04-0209-KR	2007-7029351		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	South Korea
191571-MX	04-209-MX	2007/MX/a/015909	274865	PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	Mexico
191571-NO	04-0209-NO	20080278		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	Norway
191571-NZ	04-0209-NZ	564326	564326	PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand
191571-RU	04-0209-RU	2007146669	241858	PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	Russian Federation
191571-RU2	04-0209-DIV-RU	2010150615		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	Russian Federation
191571-WO	04-0209-WO	PCT/US2006/023167		PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	PCT
191571-ZA	04-0209-ZA	2007/10878	2007/10878	PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS	South Africa
191572-AU	04-0207-AU	2005295654		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Australia
191572-CA	04-0207-CA	2583986		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Canada
191572-CN	04-0207-CN	200580034824.X		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	China
191572-EP	04-0207-EP	05808733.9		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	EPO
191572-EP2	04-0207-EP-DIV	10011664.9		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	EPO
191572-HK	04-207-HK	07113638.4		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Hong Kong
191572-HK2	04-0207-EPD HK	11110422.4		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Hong Kong
191572-IL	04-0207-IL	182493		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Israel

191572-JP	04-0207-JP	2007-536923		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Japan
191572-JP2	04-0207-JPD	2011-277345		METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B	Japan
191572-KR	04-0207-KR	2007-7008536		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	South Korea
191572-MX	04-0207-MX	MX/a/2007/004373		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Mexico
191572-NO	04-0207-NO	2007 2466		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Norway
191572-NZ	04-0207-NZ	554485	554485	METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand
191572-NZ2	04-0207-NZ-DIV	589656		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand
191572-NZ3	04-0207-NZ-DIV2	589657	589657	METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	New Zealand
191572-RU	04-0207-RU	2007117907	2391103	METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	Russian Federation
191572-WO	04-0207-WO	PCT/US2005/036950		METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	PCT
191572-ZA	04-0207-ZA	2007/03122	2007/03122	METHOD OF PREVENTING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS	South Africa
191580-CA	07-0237-CA	2673653		MYOCARDIAL PERFUSION IMAGING	Canada
191580-EP	07-0237-EP	08727357.9		MYOCARDIAL PERFUSION IMAGING	EPO
191580-HK	07-0237-HK	10102565.9		MYOCARDIAL PERFUSION IMAGING	Hong Kong
191580-JP	07-0237-JP	2009-544971		MYOCARDIAL PERFUSION IMAGING	Japan
191580-MX	07-0237-MX	MX/a/2009/007071		MYOCARDIAL PERFUSION IMAGING	Mexico

191580-WO	07-0237-WO	PCT/US2008/050117		MYOCARDIAL PERFUSION IMAGING	PCT
191587-AU	06-0222-AU	2007289037		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Australia
191587-BR	06-0222-BR	0716174-3		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Brazil
191587-CA	06-0222-CA	2662278	2662278	METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Canada
191587-CN	06-0222-CN	2007-80031995.6	ZL 200780031995.6	METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	China
191587-DE	06-0222-DE	07841736.7		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Germany
191587-EP	06-0222-EP	07841736.7	2056834	METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	EPO
191587-ES	06-0222-ES	07841736.7		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Spain
191587-FR	06-0222-FR	07841736.7		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	France
191587-GB	06-0222-GB	07841736.7		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	United Kingdom
191587-HK	06-0222-HK	09110503.0		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Hong Kong
191587-IL	06-0222-IL	197267		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Israel
191587-IN	06-0222-IN	778/KOLNP/2009		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	India

191587-IT	06-0222-IT	07841736.7		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Italy
191587-JP	06-0222-JP	2009-526935		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Japan
191587-KR	06-0222-KR	2009-7004186		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	South Korea
191587-MX	06-0222-MX	MX/a/2009/002299		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Mexico
191587-NZ	06-0222-NZ	575223		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	New Zealand
191587-RU	06-0222-RU	2009106862	2459626	METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	Russian Federation
191587-WO	06-0222-WO	PCT/US2007/077410		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	PCT
191627-AR	99-0423-AR	P000103123	24441	N-PYRAZOLE A2A RECEPTOR AGONISTS	Argentina
191627-TW	99-0423-TW	89112272	1230161	N-PYRAZOLE A2A RECEPTOR AGONISTS	Taiwan
191628-AU	05-0220-AU-CIP	2007353780		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Australia
191628-CA	05-0220-CA-CIP	2685589		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Canada
191628-CN	05-0220-CN-CIP	200780052926.3	ZL200780052926.3	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	China
191628-CN2	05-0220-CN-CIPD	20120240476		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	China
191628-EP	05-0220-EP-CIP	07783900.9		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	EPO
191628-HK	05-0220-HK-CIP	10107188.5		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Hong Kong
191628-IL	05-0220-IL-CIP	201856		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Israel
191628-JP	05-0220-JP-CIP	2010-508354	5349461	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Japan

191628-JP2	05-0220-JPD-CIP	2013-7536		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Japan
191628-KR	05-0220-KR-CIP	2009-7026178		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	South Korea
191628-MX	05-0220-MX-CIP	MX/a/2009/12369		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Mexico
191628-NO	05-0220-NO-CIP	20093543		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Norway
191628-NZ	05-0220-NZ-CIP	580940	580940	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	New Zealand
191628-RU	05-0220-RU-CIP	2009146829	2443708	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Russian Federation
191628-SG	05-0220-SG-CIP	200907228-1	156748	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Singapore
191628-WO	05-0220-WO-CIP	PCT/US2007/069190		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	PCT
191628-ZA	05-0220-ZA-CIP	2009/07565	2009/07565	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	South Africa
191630-AR	99-0424-AR-C	P000103125	33794	C-PYRAZOLE A2A RECEPTOR AGONISTS	Argentina
191630-AT	99-0424-AT-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Austria
191630-AU	99-0424-AU-F	57558/00	766712	C-PYRAZOLE A2A RECEPTOR AGONISTS	Australia
191630-BE	99-0424-BE-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Belgium
191630-BR	99-0424-BR-J	PI0011854-0		C-PYRAZOLE A2A RECEPTOR AGONISTS	Brazil
191630-CA	99-0424-CA-G	2375430	2375430	C-PYRAZOLE A2A RECEPTOR AGONISTS	Canada
191630-CH	99-0424-CH-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Switzerland
191630-CN	99-0424-CN-1	0809443.8	157102	C-PYRAZOLE A2A RECEPTOR AGONISTS	China
191630-DE	99-0424-DE-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Germany
191630-DK	99-0424-DK-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Denmark
191630-EP	99-0424-EP-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	EPO
191630-ES	99-0424-ES-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Spain
191630-FI	99-0424-FI-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Finland
191630-FR	99-0424-FR-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	France
191630-GB	99-0424-GB-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	United Kingdom
191630-GR	99-0424-GR-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Greece
191630-HK	99-0424-HK-U	02106508.0		C-PYRAZOLE A2A RECEPTOR AGONISTS	Hong Kong
191630-IE	99-0424-IE-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Ireland

191630-IL	99-0424-IL-O	147195	147195	C-PYRAZOLE A2A RECEPTOR AGONISTS	Israel
191630-IT	99-0424-IT-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Italy
191630-JP	99-0424-JP-H	2001-515875	4795591	C-PYRAZOLE A2A RECEPTOR AGONISTS	Japan
191630-KR	99-0424-KR-L	2001-7016496	511733	C-PYRAZOLE A2A RECEPTOR AGONISTS	South Korea
191630-LU	99-0424-LU-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Luxembourg
191630-MX	99-0424-MX-M	2001-013350	245023	C-PYRAZOLE A2A RECEPTOR AGONISTS	Mexico
191630-NO	99-0424-NO-N	20016351	323163	C-PYRAZOLE A2A RECEPTOR AGONISTS	Norway
191630-NZ	99-0424-NZ-P	516335	516335	C-PYRAZOLE A2A RECEPTOR AGONISTS	New Zealand
191630-PT	99-0424-PT-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Portugal
191630-SE	99-0424-SE-K	00943022.4	1192169	C-PYRAZOLE A2A RECEPTOR AGONISTS	Sweden
191630-SG	99-0424-SG-Q	200107745-2	85766	C-PYRAZOLE A2A RECEPTOR AGONISTS	Singapore
191630-TR	99-0424-TR-R	2002/00320	200200320	C-PYRAZOLE A2A RECEPTOR AGONISTS	Turkey
191630-TW	99-0424-TW-C	89112282	NI202297	C-PYRAZOLE A2A RECEPTOR AGONISTS	Taiwan
191630-WO	99-0424-WO-A	PCT/US2000/017095		C-PYRAZOLE A2A RECEPTOR AGONISTS	PCT
191630-ZA	99-0424-ZA-S	2002/0298	2002/0298	C-PYRAZOLE A2A RECEPTOR AGONISTS	South Africa
192131-AU	02-0479-AUD	2003259264		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	Australia
192131-CA	02-0479-CA-G	2492855	2492855	MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	Canada
192131-CN	02-0479-CND	03817592.4		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	China
192131-EP	02-0479-EP	03771950.3		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	EPO
192131-IL	02-0479-IL-D	166555		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	Israel
192131-JP	02-0479-JP-D	2005505626		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	Japan
192131-KR	02-0479-KR-D	1020057001708		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	South Korea
192131-MX	02-0479-MX-H	PA/a/2005/001123	280354	MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	Mexico
192131-NZ	02-0479-NZ	537975	537975	MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	New Zealand
192131-WO	02-0479-WO-D	PCT/US2003/023511		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	PCT
192131-ZA	02-0479-ZA-D	2005/00855		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	South Africa

192786-AU	05-0220-AU	2007212542	2007212542	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Australia
192786-CA	05-0220-CA	2640089	2640089	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Canada
192786-CA2	05-0220-CAD	2787759		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Canada
192786-CN	05-0220-CN	200780004423.9		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	China
192786-CN2	05-0220-CN-DIV	201110126547.2		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	China
192786-EP	05-0220-EP	07763545.6		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	EPO
192786-EP2	05-0220-EPD	12008201.1		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	EPO
192786-HK	05-0220-HK	09104112.6		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Hong Kong
192786-IL	05-0220-IL	193153		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Israel
192786-JP	05-0220-JP	2008-553396	5326156	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Japan
192786-JP2	05-0220-JPD	2012-226343		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Japan
192786-JP3	05-0220-JPD2	2012-226344		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Japan
192786-KR	05-0220-KR	2008-7019013		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	South Korea
192786-MX	05-0220-MX	MX/a/2008/009879	284744	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Mexico
192786-MX2	05-0220-DIV-MX	MX/a/2010/014060		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Mexico
192786-NO	05-0220-NO	20083395		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Norway
192786-NZ	05-0220-NZ	570239	570239	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	New Zealand
192786-RU	05-0220-RU	2008131956	2447081	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Russian Federation
192786-SG	05-0220-SG	200805720-0	145072	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	Singapore
192786-WO	05-0220-WO	PCT/US2007/003022		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	PCT
192786-ZA	05-0220-ZA	2008/06666	2008/06666	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	South Africa

192807-CA	07-0238-CA	2678515		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	Canada
192807-EP	07-0238-EP	08729731.3		INTRAVENOUS SOLUTIONS COMPRISING RANOLAZINE	EPO
192807-JP	07-0238-JP	2009-549695		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	Japan
192807-WO	07-0238-WO	PCT/US2008/053810		INTRAVENOUS SOLUTIONS COMPRISING RANOLAZINE	PCT
192808-CA	07-0238-CA2	2677931		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	Canada
192808-EP	07-0238-EP-2	08729754.5		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	EPO
192808-JP	07-0238-JP-2	2009-549698		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	Japan
192808-WO	07-0238-WO-2	PCT/US2008/053836		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	PCT
192809-CA	07-0238-CA1	2678272		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	Canada
192809-EP	07-0238-EP-1	08729743.8		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	EPO
192809-EP2	07-0238-EP-1DIV	10005464.2		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	EPO
192809-JP	07-0238-JP-1	2009-550105		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	Japan
192809-WO	07-0238-WO-1	PCT/US2008/053824		USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	PCT
192812-AT	99-0423-AT-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Austria
192812-AU	99-0423-AU-E	71324/00	760806	N-PYRAZOLE A2A RECEPTOR AGONISTS	Australia
192812-BE	99-0423-BE-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Belgium
192812-BR	99-0423-BR-I	P10011856-7		N-PYRAZOLE A2A RECEPTOR AGONISTS	Brazil
192812-CA	99-0423-CA-F	2377746	2377746	N-PYRAZOLE A2A RECEPTOR AGONISTS	Canada
192812-CH	99-0423-CH-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Switzerland
192812-CN	99-0423-CN-H	0809459.4	ZL00809459.4	N-PYRAZOLE A2A RECEPTOR AGONISTS	China
192812-CY	99-0423-CY-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Cypruss
192812-DE	99-423 DE	60007127.8	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Germany
192812-DK	99-0423-DK-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Denmark
192812-EP	99-0423-EP-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	EPO
192812-ES	99-0423-ES-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Spain
192812-FI	99-0423-FI-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Finland

192812-FR	99-0423-FR-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	France
192812-GB	99-0423-GB-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	United Kingdom
192812-GR	99-423 GR	20040400414	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Greece
192812-HK	99-0423-HK-T	02106507.1	1044952	N-PYRAZOLE A2A RECEPTOR AGONISTS	Hong Kong
192812-IE	99-0423-IE-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Ireland
192812-IL	99-0423-IL-N	147198	147198	N-PYRAZOLE A2A RECEPTOR AGONISTS	Israel
192812-IT	99-0423-IT-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Italy
192812-JP	99-0423-JP-G	2001-515876	4727880	N-PYRAZOLE A2A RECEPTOR AGONISTS	Japan
192812-KR	99-0423-KR-K	2001-7016488	463300	N-PYRAZOLE A2A RECEPTOR AGONISTS	South Korea
192812-LU	99-0423-LU-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Luxembourg
192812-MC	99-0423-MC-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Monaco
192812-MX	99-0423-MX-L	2001-013325	244944	N-PYRAZOLE A2A RECEPTOR AGONISTS	Mexico
192812-NL	99-0423-NL-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Netherlands
192812-NO	99-0423-NO-M	20016350	322457	N-PYRAZOLE A2A RECEPTOR AGONISTS	Norway
192812-NZ	99-0423-NZ-O	516334	516334	N-PYRAZOLE A2A RECEPTOR AGONISTS	New Zealand
192812-PT	99-0423-PT-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Portugal
192812-SE	99-0423-SE-J	00960112.1	1189916	N-PYRAZOLE A2A RECEPTOR AGONISTS	Sweden
192812-SG	99-0423-SG-P	2001077197	85740	N-PYRAZOLE A2A RECEPTOR AGONISTS	Singapore
192812-TR	99-0423-TR-Q	2002/00588	TR200200588	N-PYRAZOLE A2A RECEPTOR AGONISTS	Turkey
192812-WO	99-0423-WO-A	PCT/US2000/040281		N-PYRAZOLE A2A RECEPTOR AGONISTS	PCT
192812-ZA	99-0423-ZA-R	2002/0301	2002/0301	N-PYRAZOLE A2A RECEPTOR AGONISTS	South Africa
192864-AU	02-0479-AU-F	2004316372	2004316372	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Australia
192864-CA	02-0479-CA-I	2554169	2554169	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Canada
192864-CA2	02-0479-CA-IDIV	2691611		MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Canada
192864-CN	02-0479-CN-F	200480041013.8		MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	China
192864-EP	02-0479-EP-F	04705715.3	1708721	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	EPO
192864-EP2	02-0479-EP-FDIV	10011221.8	2366396	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	EPO
192864-HK2	02-0479-HK-FDIV	12102535.4		MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Hong Kong

192864-IL	02-0479-IL-F	177119	177119	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Israel
192864-JP	02-0479-JP-F	2006-551022	4818127	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Japan
192864-JP2	02-0479-DIV-JP-F	2011-034445		MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Japan
192864-KR	02-0479-KR-F	2006-7015150	1143826	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	South Korea
192864-MX	02-0479-MX-J	PA/a/2006/008521	286253	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Mexico
192864-MX2	02-0479-MX-DIV-J	MX/a/2011/000199	308545	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Mexico
192864-NO	02-0479-NO-F	20063629		MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Norway
192864-NZ	02-0479-NZ-F	548794	548794	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	New Zealand
192864-PL	02-0479-PL-F	P-380999		MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Poland
192864-RU	02-0479-RU-F	2006127167	2346693	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Russian Federation
192864-SG	02-0479-SG-F	200605068-6	124220	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Singapore
192864-SG2	02-0479-SG-FDIV	200807942-8	173924	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	Singapore
192864-WO	02-0479-WO-F	PCT/US2004/002304		MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	PCT
192864-ZA	02-0479-ZA-F	200606223	200606223	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS	South Africa